Skip to content

To Evaluate the Performance of Total 30 (Lehifilcon A) Contact Lenses in Patients Using Digital Devices for Greater Than 8 Hours Per Day 5 Days Per Week Based on Subjective Reported Data.

Performance of TOTAL30 (Lehfilcon A) Contact Lenses in Patients Using Digital Devices and 89814415

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06317038
Enrollment
35
Registered
2024-03-19
Start date
2024-03-31
Completion date
2024-12-01
Last updated
2025-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Strain

Keywords

Contact lenses, Digital Devices, Eye Comfort

Brief summary

To evaluate the performance of Total 30® (lehfilcon A) contact lenses in patients using digital devices for greater than 8 hours per day 5 days per week based on subjective reported data.

Interventions

DEVICETotal 30 Contact Lens

Patients will be give a contact lens for 1 month

Sponsors

Alcon Research
CollaboratorINDUSTRY
Tauber Eye Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Open label Observation

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Adult patients aged 18-40 of any sex and any race. * Reports habitually using digital device usage (phone, Ipad, computer, social media, video streaming) for 8 hours or more per day 5 days per week with plans to continue the habit throughout the study. * Wearing contact lenses for at least 13 hours daily 5 days per week. * Spherical refractive error between -11.00 D and +6.00D with \< -0.75 D of astigmatism. * Willing to comply with the protocol instructions. * Has read (or has had read to), understood, and signed an Informed Consent. * Willing to not use any artificial tears, rewetting drops or dry eye treatments during the study.

Exclusion criteria

* Active ocular infection or ocular inflammatory disease. * Presbyopic or pre-presbyopic that have a measured add power for reading. * Current Total 30 contact lens wearer. * Anterior basement membrane dystrophy or history of recurrent erosion syndrome or topographical abnormalities that might indicate ectasia or other corneal degenerative conditions. * Current or previous diagnosis of dry eye disease; currently using a dry eye treatment including but not limited to artificial tears, rewetting drops or prescription treatments. * History of severe / serious ocular pathology or other medical conditions that could result in an inability to safely complete the study. * Participation by the patient in any other investigational study within the past 30 days. * Unlikely to comply with protocol instructions for any reason (confusion, substance abuse, etc.). The Principal Investigator or the Medical Monitor reserves the right to declare a patient ineligible based on medical evidence that indicates the patient is unsuitable for the study. * Inability to utilize Clear Care Cleaning solution. * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Likert question about comfort satisfaction while wearing Total 30 contact lenses on a typical day (> 13 hours of daily wear) after 1 month of wear and heavy digital device usage (>8 hours daily wear).1 monthLikert Questionaire: Strongly Disagree, Disagree, Neither Agree nor Disagree, Agree, Strongly Agree

Secondary

MeasureTime frameDescription
Likert responses to insertion comfort and overall vision, and heavy digital device use on a typical day after 1 month of wear.1 monthLikert Questionaire: Strongly Disagree, Disagree, Neither Agree nor Disagree, Agree, Strongly Agree
Results of subjective ratings of patients using Total 30 lenses and heavy digital device usage with VAS diary questionnaire.1 monthVAS diary: scale 0-100 (0=No Discomfort 100= Maximal Comfort)
Report on total daily wear time and digital device usage.1 monthSurvey: Total number of hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026